Radioligand therapy using lutetium (177-Lu) vipivotide tetraxetan

Radioligand therapy using lutetium (177-Lu) vipivotide tetraxetan (procedure)

procedure
£1.00

Supplier: international · SCTID 1263784000

Also known as (4)
  • Radioligand therapy using lutetium (177-Lu) labeled prostate specific membrane antigen-617
  • Radioligand therapy using lutetium (177-Lu) labelled prostate specific membrane antigen-617
  • Radioligand therapy using lutetium (177-Lu) vipivotide tetraxetan
  • Radioligand therapy using lutetium (Lu-177) vipivotide tetraxetan

Found in

Nuclear medicine procedure Targeted radionuclide therapy

Related products

Caesium 137 brachytherapy
£1.00
Californium 252 brachytherapy
£1.00
Cobalt-60 therapy
£1.00
Dynamic non-imaging isotope study
£1.00
External beam radiation therapy using carbon ions
£1.00
External beam radiation therapy with dual headed cobalt unit
£1.00
External beam radiation therapy with radioactive caesium
£1.00
Gold 198 therapy
£1.00
In vivo neutron activation analysis
£1.00
Interstitial brachytherapy using caesium needle
£1.00
Interstitial brachytherapy using gold grain
£1.00
Interstitial brachytherapy using iridium wire
£1.00
Intravenous radionuclide therapy using samarium Sm 153 lexidronam
£1.00
Iodine 131 meta-iodobenzylguanidine therapy
£1.00
Iridium 192 brachytherapy
£1.00
Isotope static scan spleen
£1.00
Nuclear medicine imaging procedure
£1.00
Nuclear medicine study by site
£1.00
Nuclear medicine study of function
£1.00
Nuclear medicine study of systems
£1.00
Phosphorus 32 therapy
£1.00
Radioactive iodine therapy
£1.00
Radioimmunoguided surgery
£1.00
Radioimmunotherapy
£1.00
Basket
Total£0.00